Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumabMartin Gunnarsson, Jan Lycke, Clas Malmeström et al.|Annals of Neurology|2010Cited by 347
Neurofilament and glial fibrillary acidic protein in multiple sclerosisNiklas Norgren, Martin Gunnarsson, Torgny Stigbrand et al.|Neurology|2004Cited by 245
Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple SclerosisTim Spelman, Jan Lycke, Finn Sellebjerg et al.|JAMA Neurology|2021Cited by 237